194 related articles for article (PubMed ID: 26178150)
1. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
Chida R; Hisauchi I; Toyoda S; Kikuchi M; Komatsu T; Hori Y; Nakahara S; Sakai Y; Inoue T; Taguchi I
Hypertens Res; 2015 Nov; 38(11):765-9. PubMed ID: 26178150
[TBL] [Abstract][Full Text] [Related]
2. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
Taguchi I; Toyoda S; Takano K; Arikawa T; Kikuchi M; Ogawa M; Abe S; Node K; Inoue T
Hypertens Res; 2013 Jul; 36(7):608-13. PubMed ID: 23425956
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G; Gerster JC; Chiolero A; Maillard M; Fallab-Stubi CL; Brunner HR; Burnier M
J Hypertens; 2001 Oct; 19(10):1855-60. PubMed ID: 11593107
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Liberopoulos E; Christides D; Elisaf M
J Hypertens; 2002 Feb; 20(2):347. PubMed ID: 11821722
[No Abstract] [Full Text] [Related]
5. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Dang A; Zhang Y; Liu G; Chen G; Song W; Wang B
J Hum Hypertens; 2006 Jan; 20(1):45-50. PubMed ID: 16281062
[TBL] [Abstract][Full Text] [Related]
6. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters.
Nakamura M; Anzai N; Jutabha P; Sato H; Sakurai H; Ichida K
J Pharmacol Sci; 2010; 114(1):115-8. PubMed ID: 20736511
[TBL] [Abstract][Full Text] [Related]
7. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
8. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Parhofer KG; Birkeland KI; DeFronzo R; Del Prato S; Bhaumik A; Ptaszynska A
Int J Clin Pract; 2010 Jan; 64(2):160-8. PubMed ID: 19929980
[TBL] [Abstract][Full Text] [Related]
9. AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Waeber B; Burnier M
Expert Rev Cardiovasc Ther; 2003 May; 1(1):23-33. PubMed ID: 15030294
[TBL] [Abstract][Full Text] [Related]
10. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension.
Ma R; Yu J; Xu D; Yang L; Lin X; Zhao F; Bai F
J Hypertens; 2012 Jan; 30(1):210-6. PubMed ID: 22134388
[TBL] [Abstract][Full Text] [Related]
11. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
13. [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Dang AM; Liu GZ; Zhang YH; Chen GL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):882-5. PubMed ID: 17217711
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
15. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.
Baumhäkel M; Schlimmer N; Böhm M;
Int J Impot Res; 2008; 20(5):493-500. PubMed ID: 18596705
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
17. [Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].
Svishchenko IeP; Kotsiuruba AV; Mehed' OF; Bukhanevich OM; Radchenko VV; Hula NM
Fiziol Zh (1994); 2002; 48(6):31-6. PubMed ID: 12577466
[TBL] [Abstract][Full Text] [Related]
18. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
19. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
20. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Smink PA; Bakker SJ; Laverman GD; Berl T; Cooper ME; de Zeeuw D; Lambers Heerspink HJ
J Hypertens; 2012 May; 30(5):1022-8. PubMed ID: 22388234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
